single arm, non-randomized, multicenter, open label, phase 2 clinical trial in patients with advanced clear cell renal cacer

This study is a single arm, non-randomized, multicenter, open label, phase 2 clinical trial to evaluate preliminary efficacy and safety in patients with advanced clear cell renal cacer

Inclusion Criteria:

• Voluntarily participate in the study and sign the informed consent.
• Advanced clear cell renal cancer.
• At least one measurable tumor target lesion.
• Life expectancy≥3 months.
• Suitable organ functions.
• Patients who had failed at least one line therapy.
• ECOG 0-1.
• The samples of tumor tissue should be provided

Exclusion Criteria:

• Patients who had received anti-tumor therapy/radiotherapy/immunotherapy within 4 weeks.
• History of other malignant tumors within 5 years.
• Patients with CNS metastasis.
• History of active autoimmune diseases.
• Patients with poor-controlled systemic diseases after treatment.
• Patients with severe infection or requiring antibiotic treatment within 4 weeks before dosing.
• Adverse reactions related to previous treatments failed to recover to CTCAE 5.0 ≤1
• Patients who had experienced immune-related adverse events (irAE) with grade 3 or above.
• Patients who were allergic to any composition of experimental drug.
• Subjects with poor treatment compliance.
• Pregnant or lactating woman.
• Live vaccination within 28 days before first dosing.
• History of drug abuse or addiction
• Patients with active HBV or HCV, or HIV antibody positive,or Tp-Ab positive.